Andreas Muehler - 05 Jun 2025 Form 4/A - Amendment Insider Report for IMMUNIC, INC. (IMUX)

Reporting relationship: Chief Medical Officer
Issuer ticker: IMUX
Reported as of: 05 Jun 2025
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 20 Jun 2025, 17:15:10 UTC
Original report date: 09 Jun 2025
Prior SEC filing: 06 Dec 2024
Next SEC filing: 18 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Andreas Muehler

Key filing fact

Andreas Muehler filed Form 4/A - Amendment for IMMUNIC, INC. (IMUX) on 20 Jun 2025.

Key facts

This page summarizes Andreas Muehler's Form 4/A - Amendment filing for IMMUNIC, INC. (IMUX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Jun 2025, 17:15.

Change

Previous filing in this sequence was filed on 06 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001850468 Primary reporting owner

Muehler Andreas

Relationship: Chief Medical Officer
Address: 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK CITY
Signature: /s/ Andreas Muehler
Signature date: 20 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMUX transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +598,500
Change %
Price: $0.000000
Shares after: 598,500
Date: 05 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 598,500
Exercise price: $0.7729
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

SEC remarks

This Form 4/A is being filed to amend the prior Form 4 filed by the Reporting Peron on June 9, 2025 to correct an administrative error that incorrectly reported the number of stock options granted.